These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23819759)

  • 21. Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation.
    Cardillo M; Berchem G; Tarkington MA; Krajewski S; Krajewski M; Reed JC; Tehan T; Ortega L; Lage J; Gelmann EP
    J Urol; 1997 Jul; 158(1):212-6. PubMed ID: 9186362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effect of finasteride and dutasteride on chromogranin A levels.
    Sciarra A; Salciccia S; Nesi G; Cattarino S; Alfarone A; Gentilucci A; Gentile V
    Anticancer Res; 2010 Nov; 30(11):4737-42. PubMed ID: 21115933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
    J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H; Kanetake H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract]   [Full Text] [Related]  

  • 25. Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation.
    Simanainen U; McNamara K; Gao YR; Handelsman DJ
    Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1335-43. PubMed ID: 19366880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
    Erdoğru T; Ciftcioglu MA; Emreoglu I; Usta MF; Koksal T; Ozbilim G; Gulkesen KH; Baykara M
    Urol Int; 2002; 69(4):287-92. PubMed ID: 12444285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.
    Festuccia C; Angelucci A; Gravina GL; Muzi P; Vicentini C; Bologna M
    J Cancer Res Clin Oncol; 2005 Apr; 131(4):243-54. PubMed ID: 15650886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
    BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T; Hashimoto Y; Takahashi K
    Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term oral administration of 5α-reductase inhibitor attenuates erectile function by inhibiting autophagy and promoting apoptosis of smooth muscle cells in corpus cavernosum of aged rats.
    Zhang MG; Wang XJ; Shen ZJ; Gao PJ
    Urology; 2013 Sep; 82(3):743.e9 -15. PubMed ID: 23876578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lovastatin-induced apoptosis in prostate stromal cells.
    Padayatty SJ; Marcelli M; Shao TC; Cunningham GR
    J Clin Endocrinol Metab; 1997 May; 82(5):1434-9. PubMed ID: 9141529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
    Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
    J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride.
    Rittmaster RS; Manning AP; Wright AS; Thomas LN; Whitefield S; Norman RW; Lazier CB; Rowden G
    Endocrinology; 1995 Feb; 136(2):741-8. PubMed ID: 7835306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.
    Schatzl G; Madersbacher S; Gsur A; Preyer M; Haidinger G; Haitel A; Vutuc C; Micksche M; Marberger M
    Prostate; 2002 Jul; 52(2):130-8. PubMed ID: 12111704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and bioactivity of new Finasteride conjugate.
    Shuang Z; Jiazhen W; Lijuan Y; Zhuo L; Dahai Y; Jinfeng L; Jing Y; Yongtao L; En-Si W; Xuexun F
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3439-42. PubMed ID: 21515045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M; Bartsch W; Thomsen M; Voigt KD
    J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
    Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
    J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5 alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia.
    Weisser H; Tunn S; Debus M; Krieg M
    Steroids; 1994 Nov; 59(11):616-20. PubMed ID: 7535480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
    J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
    Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.